Invention Grant
- Patent Title: Bladder cancer tumor marker, antibody and use thereof
- Patent Title (中): 膀胱癌肿瘤标志物，抗体及其用途
-
Application No.: US13814446Application Date: 2011-08-12
-
Publication No.: US09073995B2Publication Date: 2015-07-07
- Inventor: Chong Li , Zusen Fan , Honglian Zhang , Zhonghua Dai , Haidong Tang , Jun Chen
- Applicant: Chong Li , Zusen Fan , Honglian Zhang , Zhonghua Dai , Haidong Tang , Jun Chen
- Applicant Address: CN Beijing
- Assignee: Institute of Biophysics, Chinese Academy of Sciences
- Current Assignee: Institute of Biophysics, Chinese Academy of Sciences
- Current Assignee Address: CN Beijing
- Agency: Osha Liang LLP
- Priority: CN201010251384 20100811
- International Application: PCT/CN2011/001345 WO 20110812
- International Announcement: WO2012/019437 WO 20120216
- Main IPC: G01N33/53
- IPC: G01N33/53 ; C07K16/00 ; C07K16/28 ; C07K14/705 ; G01N33/574 ; G01N33/68 ; C12N15/113 ; C12Q1/48 ; C12Q1/02 ; A61K47/48 ; A61K51/10 ; A61K45/06 ; A61K39/395 ; C07K16/30 ; C12N9/10
Abstract:
Provided in the present invention are an aberrantly glycosylated integrin, AG-α3β1, and use thereof as a bladder cancer marker. Also provided in the present invention are a hybridoma cell generating an anti-AG-α3β1 monoclonal antibody, a monoclonal antibody BCMab1 secreted by the same, and use of BCMab1 in the preparation of a medicament for the treatment of bladder cancer. Also provided in the present invention is use of inhibitors of GAL3ST2 and N-acetylgalactosaminyltransferase 1 in the preparation of a medicament for the treatment of bladder cancer.
Public/Granted literature
- US20130164216A1 BLADDER CANCER TUMOR MARKER, ANTIBODY AND USE THEREOF Public/Granted day:2013-06-27
Information query
IPC分类:
